Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes.
Caballero JC, Dávila J, López-Pavía M, Such E, Bernal T, Ramos F, Calabuig M, Hernández Sánchez JM, Pomares H, Sánchez Barba M, Abáigar M, González B, Merchán B, Sancho-Tello R, Callejas M, Muñoz-Novas C, Cerveró C, Sanz G, Hernández Rivas JM, Díez Campelo M.
Caballero JC, et al. Among authors: munoz novas c.
Ther Adv Hematol. 2024 Jan 4;15:20406207231218157. doi: 10.1177/20406207231218157. eCollection 2024.
Ther Adv Hematol. 2024.
PMID: 38186638
Free PMC article.